Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Issues Earnings Results

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) posted its earnings results on Thursday. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74), Yahoo Finance reports. Calliditas Therapeutics AB (publ) had a negative return on equity of 133.08% and a negative net margin of 40.19%. The company had revenue of $28.43 million during the quarter, compared to the consensus estimate of $35.78 million.

Calliditas Therapeutics AB (publ) Stock Performance

Shares of Calliditas Therapeutics AB (publ) stock opened at $22.42 on Friday. The company’s fifty day simple moving average is $20.60 and its 200-day simple moving average is $21.19. Calliditas Therapeutics AB has a 1-year low of $15.25 and a 1-year high of $29.30. The company has a current ratio of 3.13, a quick ratio of 3.08 and a debt-to-equity ratio of 2.89.

Analyst Upgrades and Downgrades

Separately, HC Wainwright cut their target price on shares of Calliditas Therapeutics AB (publ) from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Friday.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.